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activates apoptosis by plasma membrane
death receptor pathway, activation of caspase
enzymes, and release of cytochrome c from
mitochondria. Although blood flow to the
spinal cord is restored during reperfusion,
the motor neurons that seem to survive
ischemic insult may undergo delayed selec-
tive death, particularly 7 days after the pro-
cedure.4 Despite that the etiology of delayed
selective neuronal death has been proposed to
be the activation of Akt protein, Grp78, and
caspase 12 proteins, further studies should be
warranted. In the present study, the authors
claimed the protective effect of edaravone
on spinal cord injury according to the his-
tologic examination and levels of ROS.
However, it is known that these neurons
might be apoptotic despite the normal cel-
lular architecture seen on the hematoxylin
and eosin (H & E) staining. The authors did
not focus on apoptotic mechanisms and dem-
onstrated only necrotic (ghost) neurons with
H & E staining without considering the
neurons undergoing apoptosis. In this re-
gard, we believe that addition of the neu-
ronal apoptosis would increase the statisti-
cal power of this study.
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Reply to the Editor:
We thank Dr AK for his insightful com-
ments on our recently published article.
Paraplegia or paraparesis occurring in the
late postoperative period is well described
in the literature. The mechanism of this de-
layed spinal deficit is presumed to be related
with apoptosis. Sakurai and colleagues1 eval-
uated the relationship between delayed para-
plegia and apoptosis using immunohistochem-
ical techniques. In their experimental study,
the transient spinal ischemic time was 15
minutes. Two days after the reperfusion, the
mean Johnson score was 4.9  0.894, and
3 of the 5 rabbits had normal hind-limb
function. In our study,2 we applied a spinal
ischemic time of 30 minutes. Two days
after the reperfusion, all rabbits in the con-
trol group were completely paraplegic with
a Johnson score of 0. The focus of our
investigation was to assess whether pro-
phylactic administration of edaravone could
suppress necrosis and not apoptosis of the
spinal cord. Consequently, a longer spinal
ischemic time was employed and only
hematoxylin-eosin staining was used for
histopathologic evaluation. As suggested by
AK, motor neurons that appear intact on he-
matoxylin and eosin staining as a result of the
prophylactic administration of edaravone
might suffer delayed apoptosis-related injury.
Because we did not use any marker for
apoptosis in our study, we are not in a
position to comment on this. However, we
agree with Dr AK that further studies need
to be undertaken to clarify this issue. We
are indeed planning to embark on a protocol
that involves the use of markers of apopto-
sis in a model of shorter spinal ischemic
time and longer duration of observation.
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Surgical treatment for congestive
heart failure with autologous adult
stem cell transplantation
To the Editor:
Patel and colleagues1 have provided further
evidence of the benefit of autologous stem
cell transplantation in patients with isch-
emic cardiomyopathy. However, even if, in
the past years, observational studies and
some randomized controlled trials have es-
tablished that autologous stem cell transplan-
tation has led to significant improvement in
myocardial infarction and congestive heart
failure, this study unfortunately has not spe-
cifically addressed several clinically relevant
questions: What dose of CD34 cells for
stem cell therapy in this area should we use?
Furthermore, what is the best cell type and
the best cell dose for each cell type?
In recent studies, doses of CD34 cells
ranging from 106 to 108 have been used;
however, if the optimum dose of CD34
cells needed is proven to be much less than
106, procedures involved in collecting suf-
ficient amounts for therapeutic use can be
less time-consuming and thus potentially
cost-saving. Furthermore, the expression of
CD34 surface antigen characterizes a het-
erogeneous population of cells including
hematopoietic progenitor cells, endothelial
progenitor cells, mature endothelial cells,
and tissue-committed stem cells as recently
reported.2 It is still not clear whether the
beneficial effect of these cells in regenera-
tion can be explained by the transdifferen-
tiation of hematopoietic stem cells, the
paracrine secretion of angiopoietic factors
from bone marrow-derived stem cells,3 or the
presence of tissue-committed stem cells for
myocardium or endothelium. We believe that
there is a pressing need to standardize thera-
peutic protocols to allow tailor-made thera-
pies for these patients.
Vincenzo Pitini, MD
Giuseppe Altavilla, MD
Carmela Arrigo, MD
Department of Medical Oncology and Bone
Marrow Transplantation
University of Messina, Italy
Letters to the Editor
The Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 5 1213
References
1. Patel AN, Geffner L, Vina RF, Saslavsky J,
Urschel HC, Kormos R, et al. Surgical treat-
ment for congestive heart failure with autolo-
gous adult stem cell transplantation: a prospec-
tive randomised study. J Thorac Cardiovasc
Surg. 2005;130:1631-8.
2. Kucia M, Ratajczak J, Reca R, Janowska-
Wieczorek A, Ratajczak MZ. Tissue-specific
muscle, neural and liver stem/progenitor cells
reside in the bone marrow, respond to an
SDF-1 gradient and are mobilized into pe-
ripheral blood during stress and tissue injury.
Blood Cells Mol Dis. 2004;32:52-7.
3. Majka M, Janowska-Wieczorek A, Ratajczak
J, Ehrenman K, Pietrzykowsky Z, Kowalska
A, et al. Numerous growth factors, cytokines,
and chemokines are secreted by human
CD34 cells, myeloblasts, erythroblasts, and
megakaryoblasts and regulate normal hema-
topoiesis in an autocrine/paracrine manner.
Blood. 2001;97:3075-85.
doi:10.1016/j.jtcvs.2005.12.048
Reply to the Editor:
I thank Dr Vincenzo Pitini for his com-
ments and concerns regarding our recently
published article.1 The salient questions re-
garding the optimal cell type, dose, purity,
method of injection, and final fate of the
cells are all important and need to be ad-
dressed. However, this article was the first
randomized study to address some of the
more basic issues related to the use of cell
therapy in an adjunctive fashion to revas-
cularization. Because there is a chance of
overlap between collateral vessels and re-
gions of cell injection that were not directly
revascularized, we wanted to see whether
there was a difference over and above re-
vascularization. This was found to be true.
To address the other questions I will go in
order. First, cell type along with purity was
thought to be very important. The basic and
preclinical models using various fractions
of blood or bone marrow, adipose, myo-
blasts, umbilical cord, or amniotic cells
have all shown promise of cardiac differ-
entiation. However, myoblasts, blood, and
bone marrow have been used clinically
showing early promising results; only myo-
blasts have problems related to ventricular
arrhythmias. Both blood and bone marrow
have been used as a relativity pure formu-
lation of CD 34, AC 133, mesenchy-
mal cells, or a mixed population based on
density gradients. Neither has truly shown
a benefit over the other thus far. Therefore,
no one really knows the optimal cell type
or purity yet. As to the dose of cells, ac-
cording to the work of Stamm and col-
leagues2 on AC 133, there has been no
dose-response curve.2 Currently, at the Uni-
versity of Pittsburgh, we have a Food and
Drug Administration-approved Phase I
prospective randomized blinded trial for 3
arms of low, medium, and high doses of
CD 34 and 1 placebo arm for coronary
artery bypass grafting and cells for patients
with ejection fractions of less than 40%.
This may help lead to more answers at
least for this cell type. However, dosing
trials will be needed for each different cell
type used and each clinical indication de-
sired. The method of injection is also a
variable related to success of delivery and
possible retention of cells in the tissue. We
have been using a modified needle with
side holes injected on an angle and left in
the tissue for a short period of time to
decrease leakage. This has been successful,
but the use of biodegradable gels is prom-
ising but not yet clinically applicable. We
have also started partnering with industry
to develop an automated cell injection sys-
tem to help increase the reliability of cell
delivery in terms of accurate doses. Finally,
the fate of the cells has led to many pro-
posed mechanisms from differentiation,
to fusion, to a paracrine response. We do
not have the answers yet in humans, but we
do have a Food and Drug Administration-
approved trial for the CD 34 cells in-
jected into the hearts of patients with a
ventricular assist device implanted as a
bridge to transplant. Half of the heart is
injected with cells, and the other half is
injected with a placebo. The heart is ex-
planted at the time of transplantation, and
the tissue is analyzed for cellular changes.
Again, the issue arises because the cells
cannot be marked and tracked once in vivo.
Overall, the early clinical trials are prom-
ising, but there is a lot of research that still
needs to be performed to help understand
the clinical improvements seen in our and
many other patients.
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